Clinical Trial Update: Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial [NA]

View source ↗

Summary

Clinical trial update comparing MicroPort's Firehawk drug-eluting stent to Xience V in coronary artery disease; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Firehawk DES (firehawk drug-eluting stent)
• XIENCE V (everolimus-eluting stent)

Snippet

Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd. | Conditions: Coronary Artery Disease | NA | Status: COMPLETED | Results posted: 2018-02-22